ZEGALOGUE was studied in a clinical trial program of people with type 1 diabetes. Two trials were conducted in adults, and a third trial was conducted in children and adolescents aged 6 to 17 years. In all 3 trials, the results of participants who received ZEGALOGUE were compared with the results of those who received a placebo following insulin-induced low blood sugar.
The primary goal in all 3 trials was to measure the time to blood sugar recovery, defined as an increase in blood sugar of at least 20 mg/dL from the time of administration, without additional intervention.
In clinical trials, median time to blood sugar recovery was 10 minutes in adults, adolescents, and children.
of adults recovered in 15 minutes
Reliable results: adults studied recovered with a single dose
In another trial, 88% of adult patients recovered in 15 minutes.
of children and adolescents recovered in 15 minutes
Reliable results: children and adolescents studied recovered with a single dose
In clinical trials, the most common side effects of ZEGALOGUE in adults were:
In clinical trials, the most common side effects of ZEGALOGUE in children and adolescents were: